Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 600 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

VANT-BP

Validation of A Non-Invasive Wearable Technology to Measure Blood Pressure in Cardiac Patients. The VANT- BP study (Trial Not Registered)

Currently recruiting

VANTAGE

VANTAGE Clinical Trial: (Evaluation of TAVI using the NAVITOR valve in a Global Investigation) (NCT04788888)

Currently recruiting

VAPOR-C

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial (NCT04316013)

Currently recruiting

VECTORS

An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease [VECTORS] (NCT06257706)

Currently recruiting

VELOCITY-HNSCC GS-US-699-7184

A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status (NCT06727565)

Currently recruiting

VENTURA-LT

An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) (NCT05518149)

Currently recruiting

VENTYX

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn's Disease (NCT05688852)

Currently recruiting

VERTEX

A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX 670 in Adult Subjects with Myotonic Dystrophy Type 1 (NCT06185764)

Currently recruiting

VERTEX

A Phase 1/2, Randomized, Double-blind, Placebo controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 (NCT06185764)

Coming soon

Vertex OLE

An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type I (NCT06926621)

Currently recruiting

VIALE-T

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T) (NCT04161885)

Currently recruiting

VISAD

Evaluating Vi-polysaccharide vaccine responses in specific antibody deficiency patients receiving immunoglobulin replacement (VISAD Study) (ACTRN12621001059853)

Recently completed/closed

Vista Study

Navitor Post-Market Clinical Follow Up Study [VISTA Study] (NCT06008080)

Coming soon

VX20-121-102

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF) (NCT05033080)

Recently completed/closed

VX20-121-103

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation (NCT05076149)

Recently completed/closed

VX20-121-104

A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (NCT05444257)

No longer recruiting

VX21-522-001

A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy (NCT05668741)

Currently recruiting

WITHDRAW-AF

WITHDRAWal of heart failure directed therapies in recovered Atrial Fibrillation mediated cardiomyopathy- WITHDRAW-AF study (ACTRN12621000896875)

Currently recruiting

WOMEN'S HEALTH

Pregnancy and Multiple Sclerosis Outcomes (Trial Not Registered)

Recently completed/closed

XENON 301-XTOLE2

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures (NCT05614063)

Currently recruiting
28 29 30 31